Urology
Volume 69, Issue 2 , Pages 334-337 , February 2007

Long-Term Prostate Cancer Control Using Palladium-103 Brachytherapy and External Beam Radiotherapy in Patients with a High Likelihood of Extracapsular Cancer Extension

  • Michael Dattoli

      Affiliations

    • Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida
    • Corresponding Author InformationReprint requests: Michael Dattoli, M.D., Dattoli Cancer Center, 2803 Fruitville Road, Sarasota, FL 34217.
    • ,
  • Kent Wallner

      Affiliations

    • Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington
    • Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, Washington
    • Group Health Cooperative, Seattle, Washington
    • ,
  • Lawrence True

      Affiliations

    • Department of Pathology, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Jennifer Cash

      Affiliations

    • Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida
    • ,
  • Richard Sorace

      Affiliations

    • Dattoli Cancer Center and Brachytherapy Research Institute, Sarasota, Florida

Received 10 March 2006 ,Accepted 21 September 2006.

References 

  1. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endo/Hypertherm. 1987;3:131–139
  2. Cooperberg M, Lubeck D, Meng M, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  3. Hakenberg O, Wirth M, Hermann T, et al. Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Urol Int. 2002;70:15–20
  4. Pisansky T, Blute M, Hillman D, et al. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002;95:513–519
  5. Khan MA, Partin AW. Partin tables: past and present. BJU Int. 2003;92:7–11
  6. Febles C, Valicenti R. Combining external beam radiotherapy with prostate brachytherapy: issues and rationale. Urology. 2004;64:855–861
  7. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  8. Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111–117
  9. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  10. Merrick G, Butler W, Wallner K, et al. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA <20 ng/ml. Am J Clin Oncol. 2004;27:611–615
  11. Merrick G, Butler W, Lief JH, et al. Biochemical outcome for hormone-naive intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Brachytherapy. 2002;1:95–101
  12. Stock RG, Cahlon O, Cesaretti J, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352–1359
  13. Roy AV, Brower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem. 1998;17:1093–1102
  14. Dattoli MJ, Wallner KE, Sorace R, et al. Planned extracapsular seed placement using palladium-103 for prostate brachytherapy. J Brachyther Int. 2000;16:35–43
  15. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85:2630–2637
  16. Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by prostate brachytherapy? (An analysis based on postimplant dosimetry). Int J Radiat Oncol Biol Phys. 2001;51:1196–1199
  17. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:178–189
  18. Critz F. Summary of simultaneous irradiation for prostate cancer. Urology. 2004;64:633–636

PII: S0090-4295(06)02249-7

doi: 10.1016/j.urology.2006.09.045

Urology
Volume 69, Issue 2 , Pages 334-337 , February 2007

Article Tools

* Image Usage & Resolution